AI assistant
Marker Therapeutics, Inc. — Director's Dealing 2020
Mar 12, 2020
35150_dirs_2020-03-12_e4509b3a-c360-4e71-a1d4-1fe5350f1a82.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Marker Therapeutics, Inc. (MRKR)
CIK: 0001094038
Period of Report: 2020-03-10
Reporting Person: Garrett Gerald (Vice President, Clinical Ops.)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-03-10 | Employee Stock Option (Right to Buy) | $2.12 | A | 1700 | Acquired | 2030-03-10 | Common Stock (1700) | Direct |
| 2020-03-10 | Employee Stock Option (Right to Buy) | $2.12 | A | 38300 | Acquired | 2030-03-10 | Common Stock (38300) | Direct |
Footnotes
F1: Represents a bonus for 2019 performance granted under the Company's 2014 Omnibus Stock Ownership Plan. This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date.
F2: This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date.